Apogee Therapeutics, Inc.
APGENASDAQHealthcare● Active
$83.09
$-3.83(-4.41%)
Market Cap$5.1B
P/E Ratio—
52W High$95.315
52W Low$34.34
Apogee Therapeutics, Inc. (APGE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
APGE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$1.06
Est. -$1.07 · +0.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
✓ 3-Quarter EPS Beat Streak
APGE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$1.10 | — | — | — | $0.02B | — |
| — Q2 FY2026 | May 11, 2026 | -$1.07 | -$1.06 | +0.9% | — | — | — |
| ▲ Q1 FY2026 | Mar 2, 2026 | -$1.05 | -$1.03 | +1.9% | — | — | — |
| — Q4 FY2025 | Nov 10, 2025 | -$1.12 | -$1.11 | +0.9% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$1.03 | -$1.13 | -9.7% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$1.19 | -$0.95 | +20.2% | — | — | — |
| ▼ Q1 FY2025 | Mar 3, 2025 | -$0.94 | -$1.19 | -26.6% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.88 | -$0.86 | +2.2% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$1.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026
EPS Actual
-$1.06
EPS Est.
-$1.07
EPS Surpr.
+0.9%
Revenue
—
Q1 FY2026
Mar 2, 2026Beat
EPS Actual
-$1.03
EPS Est.
-$1.05
EPS Surpr.
+1.9%
Revenue
—
Q4 FY2025
Nov 10, 2025
EPS Actual
-$1.11
EPS Est.
-$1.12
EPS Surpr.
+0.9%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$1.13
EPS Est.
-$1.03
EPS Surpr.
-9.7%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.95
EPS Est.
-$1.19
EPS Surpr.
+20.2%
Revenue
—
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
-$1.19
EPS Est.
-$0.94
EPS Surpr.
-26.6%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.86
EPS Est.
-$0.88
EPS Surpr.
+2.2%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.29 | $-1.29 | $-1.29 | 6 |
| Q3 FY2027 | $-1.25 | $-1.25 | $-1.25 | 3 |
| Q2 FY2027 | $-1.20 | $-1.20 | $-1.20 | 5 |
| Q1 FY2027 | $-1.16 | $-1.16 | $-1.16 | 3 |
| Q4 FY2026 | $-1.23 | $-1.23 | $-1.23 | 6 |
| Q3 FY2026 | $-1.22 | $-1.13 | $-1.04 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +0.9% | $83.03 | $84.60 | +1.89% |
| ▲ Q1 FY2026 | Mar 2, 2026 | +1.9% | $70.00 | $70.92 | +1.31% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +0.9% | $54.71 | $56.77 | +3.77% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -9.7% | $35.39 | $34.65 | -2.09% |
| ▲ Q2 FY2025 | May 12, 2025 | +20.2% | $37.29 | $39.58 | +6.14% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -26.6% | $31.44 | $31.39 | -0.16% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +2.2% | $60.46 | $57.35 | -5.14% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +6.3% | $40.50 | $44.46 | +9.78% |
Q2 FY2026+1.89%
Report Date
May 11, 2026
EPS Beat/Miss
+0.9%
Price Before
$83.03
Price After
$84.60
Q1 FY2026+1.31%
Report Date
Mar 2, 2026
EPS Beat/Miss
+1.9%
Price Before
$70.00
Price After
$70.92
Q4 FY2025+3.77%
Report Date
Nov 10, 2025
EPS Beat/Miss
+0.9%
Price Before
$54.71
Price After
$56.77
Q3 FY2025-2.09%
Report Date
Aug 11, 2025
EPS Beat/Miss
-9.7%
Price Before
$35.39
Price After
$34.65
Q2 FY2025+6.14%
Report Date
May 12, 2025
EPS Beat/Miss
+20.2%
Price Before
$37.29
Price After
$39.58
Q1 FY2025-0.16%
Report Date
Mar 3, 2025
EPS Beat/Miss
-26.6%
Price Before
$31.44
Price After
$31.39
Q4 FY2024-5.14%
Report Date
Nov 12, 2024
EPS Beat/Miss
+2.2%
Price Before
$60.46
Price After
$57.35
Q3 FY2024+9.78%
Report Date
Aug 12, 2024
EPS Beat/Miss
+6.3%
Price Before
$40.50
Price After
$44.46
Avg Beat Reaction+2.96%
Avg Miss Reaction-1.13%
Beat Rate6 / 8 quarters
Largest Move+9.78% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: APGE ends December
Apogee Therapeutics, Inc. (APGE) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-1.06 (in line with the analyst consensus of $-1.07). APGE has beaten EPS estimates for 3 consecutive quarters. The next APGE earnings date is expected around September 1, 2026.
Each quarter, investors track APGE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. APGE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
APGE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
APGE earnings · 4 questionsApogee Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. APGE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; APGE historically reports after market close (AMC).
APGE earnings datewhen is APGE earningsAPGE next earnings datewhen does APGE report earningsAPGE earnings calendar
▸ Source: FMP · Apogee Therapeutics, Inc. SEC filings · US GAAP · Apogee Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026